

## PRESS RELEASE

# Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update

**Lund, Sweden April 14, 2021** Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2021 at 8:00 CET on April 22, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Webcast," and will also be made available online after the call. [Link to presentation](#)

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 8 50 55 83 75

United Kingdom: +44 333 300 90 35

United States: +1 833 526 83 82

The webcast will be available on <https://streams.eventcdn.net/hansa/2021q1/>

### Updated Calendar and Events 2021

April 22, 2021	Interim report for Jan-Mar 2021
April 28, 2021	Redeye Orphan Drugs Event, Stockholm (virtual)
May 5, 2021	Kempen Life Sciences Conference, Amsterdam (virtual)
May 7+14, 2021	Truist US Roadshow (virtual)
May 11, 2021	Nordnet/Proinvestor Biotech event, Copenhagen (virtual)
May 12, 2021	Annual General Meeting 2021
May 19, 2021	RBC Global Healthcare Conference, NYC (virtual)
May 25, 2021	ABG Life Science Seminar, Stockholm (virtual)
June 1, 2021	Jefferies Healthcare Conference, London (virtual)
June 16, 2021	Citi's 2021 European Healthcare Conference (virtual)
July 15, 2021	Interim report for Jan-Jun 2021
Aug 25, 2021	Handelsbanken Life Science Innovation Seminar, Stockholm
Sep 1, 2021	Pareto Healthcare Conference, Stockholm (virtual)
Oct 21, 2021	Interim report for Jan-Sep 2021

### **About Hansa Biopharma**

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.

For more information:

Klaus Sindahl, *Head of Investor Relations*

**M:** +46 (0) 709-298 269

**E:** [klaus.sindahl@hansabiopharma.com](mailto:klaus.sindahl@hansabiopharma.com)

Katja Margell, *Head of Corporate Communications*

**M:** +46 (0) 768-198 326

**E:** [katja.margell@hansabiopharma.com](mailto:katja.margell@hansabiopharma.com)